Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:

NCT ID: NCT05135897 Recruiting - Healthy Clinical Trials

The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments

FundECT
Start date: September 27, 2021
Phase:
Study type: Observational

The study will apply state of the art radiology through advanced magnetic resonance imaging (MRI) techniques to investigate structural and functional brain effects of electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS).

NCT ID: NCT05135793 Completed - Healthy Clinical Trials

Bioequivalence Study of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)

Start date: January 19, 2021
Phase: Phase 1
Study type: Interventional

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Vonoprazan From Topoprazan 20 mg Tablets (Hikma Pharma, Egypt) Versus Takecab 20 mg Tablets (Takeda Pharmaceutical Co. Ltd., Japan)

NCT ID: NCT05135169 Not yet recruiting - Healthy Clinical Trials

Multi-organ Transit Time Acquisition Using Contrast Ultrasound

Start date: July 2022
Phase: Phase 4
Study type: Interventional

Echocardiographic contrast will be administered to volunteers for the purpose of measuring transit time through various organs/vascular beds

NCT ID: NCT05132049 Not yet recruiting - Healthy Clinical Trials

Pharmacokinetics and Safety Profiles After Administration of DA-5211 and Co-administration of DA-5211-R1 and DA-5211-R2 in Healthy Adult Volunteers

Start date: December 13, 2021
Phase: Phase 1
Study type: Interventional

Pharmacokinetics and safety Profiles after administration of DA-5211 and co-administration of DA-5211-R1 and DA-5211-R2 in healthy adult volunteers

NCT ID: NCT05132023 Completed - Healthy Clinical Trials

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Start date: March 26, 2019
Phase: Phase 1
Study type: Interventional

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Empagliflozin & Metformin HCL from Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

NCT ID: NCT05130619 Recruiting - Healthy Clinical Trials

Human Auto-ethanol Formation and Acetate Signaling

HotFacets
Start date: November 10, 2021
Phase: N/A
Study type: Interventional

The HotFacets study is a randomized, controlled, cross-over meal study that investigates the acute effects of alcohol consumption on short-chain fatty acids dynamics, energy metabolism, and biomarkers. Despite the negative health consequences of chronic alcohol abuse, observational and cohort studies associate moderate alcohol consumption with a 20-30 % lower risk of cardiovascular diseases (CVD) and Type 2 Diabetes Mellitus (T2DM), compared to abstainers. Based on the J-shaped relationship between alcohol intake and the risk of cardiometabolic diseases, ½-2 standard drinks/day can be considered as moderate alcohol consumption. The interpretation of the J-shaped relationship has been criticized mainly due to potential confounding from the selected reference group and uncontrolled lifestyle factors. Longer, well-designed randomized controlled trials are lacking to infer causality and to clarify the mechanism of action for the acute and chronic effects of moderate alcohol consumption on cardiometabolic health and energy homeostasis. However, some aspects of alcohol metabolism and biomarker validation could inform such a study. HotFacets is set to generate insight into the effects of acute alcohol intake on SCFA dynamics in blood, urine, and faeces; into the dose-response relationship with REE, thermogenesis, substrate oxidation, and alcohol biomarkers; and to explore potential low levels of alcohol produced in the gut.

NCT ID: NCT05130164 Not yet recruiting - Healthy Clinical Trials

Age Estimation From Pulp Cavity Analysis Using Cone Beam Computed Tomographic Images for Forensic Purposes

Start date: December 2021
Phase:
Study type: Observational

Forensic odontology is a branch of forensic science that utilizes a dentist's expertise in identification of individuals for whom traditional methods of identification aren't accessible due to a lack of common identification features. Medico-legal issues, natural catastrophes such as tsunamis, earthquakes, and explosions, death verification in monetary concerns, religious and social reasons are all examples of situations that require identification. Age, stature, sex and ethnicity are the "big four" determinants of personal identification. Dental age estimation has the benefit of that teeth are less influenced by external physical, chemical, or mechanical variables than other portions of the skeleton. Secondary dentin deposition in human teeth progresses with age that results in reduction in the size of the tooth pulp cavity which can be assessed as an age indicator. A significant relationship between pulp width and age was originally discovered in a study by Kvaal et al., 1995 who created regression formulae for age prediction using periapical radiograph by measuring of pulp size. Also, the assessment of pulp/tooth volume ratio relying on the gradual reduction in pulp volume produced by continuous apposition of dentin during life is one well-known dental age estimation approach. Cone beam computed tomography (CBCT) provides accurate three-dimensional images of the maxillofacial area. In addition, CBCT may be beneficial in some forensic situations, as it has massive benefits for post-mortem forensic imaging, as it offers skeletal imaging with high resolution, cheap cost, simplicity and portability. CBCT can be used in forensic age assessment since it is non-invasive and allows for the reconstruction of images in multiple planes to display anatomical and imaged elements in distinct planes. Our hypothesis is that pulp space analysis is totally different between different ages and that there is a correlation between age and pulp space analysis that could be of a forensic significance for age estimation in the investigated population.

NCT ID: NCT05128058 Recruiting - Healthy Clinical Trials

A Target Occupancy Study With Ritlecitinib.

Start date: October 22, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1, open label, two-arm study to assess target occupancy and functional inhibition of JAK3 and TEC kinases by Ritlecitinib in healthy adult participants

NCT ID: NCT05127746 Not yet recruiting - Healthy Clinical Trials

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD Profiles of DA-5207 TDS in Healthy Adults

Start date: November 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of DA-5207 transdermal delivery system in healthy adults

NCT ID: NCT05125211 Not yet recruiting - Healthy Clinical Trials

Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects

Start date: November 20, 2021
Phase: Phase 1
Study type: Interventional

This trial is conducted in China. The aim of this clinical trial is to assess the safety , tolerability and pharmacokinetics profiles of GB001 by single ascending dose and multiple ascending doses in healthy subjects after topical buccal delivery.